Here are the S-3 shelf registrations from X4 Pharmaceuticals, Inc. (XFOR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow XFOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XFOR filings page.
X4 Pharmaceuticals filed a shelf registration on Form S-3 to offer up to $300,000,000 of securities, including common stock, preferred stock, debt securities, warrants and/or units. The filing includes an at-the-market sales agreement with Jefferies to sell up to $75,000,000 of common stock.
The prospectus discloses that X4 has one approved product, XOLREMDI® (mavorixafor), and is conducting a global Phase 3 4WARD trial in chronic neutropenia targeting up to 176 patients with full enrollment aimed for the end of Q3 2026. The base prospectus and any prospectus supplement will specify terms and intended uses of proceeds.